The problem. Imaging-based methods (MERFISH, seqFISH+) are powerful but were largely bespoke, lab-built systems — hard to standardise, hard to scale across a facility. For spatial biology to become routine, especially in a clinical/translational setting, the imaging approach had to become a reliable commercial platform with defined panels and reproducible output.

The idea. Xenium is 10x Genomics’ in-situ imaging platform: targeted gene panels read out by cyclic fluorescence imaging at subcellular resolution, integrated in this paper with matched single-cell and Visium data to map a tumor microenvironment. The contribution is partly the platform itself and partly the demonstration of cross-modal integration — imaging, spatial-capture, and dissociated single-cell views of the same tissue.

Why it matters. This is concretely relevant to the BIDMC STU, which works with platforms exactly like this. It lands the whole day’s arc in the present: MERFISH’s principle, now an instrument you can run, benchmarked against the capture methods (the Nat Commun 2025 platform comparisons from day 3 pit Xenium against MERSCOPE/CosMx). Understanding Xenium’s targeted-panel, subcellular trade-offs is understanding the tool the role centres on.

Verdict. Foundational as the reference paper for a major commercial imaging platform; targeted panels and cost are the standing trade-offs. Read it as where imaging-based spatial becomes routine infrastructure — and the platform the STU work most directly touches.